Aligos Therapeutics Reports Q2 2025 Progress and Results

Aligos Therapeutics, Inc. ( (ALGS) ) has released its Q2 earnings. Here is a breakdown of the information Aligos Therapeutics, Inc. presented to its investors.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing advanced therapies for liver and viral diseases, with a focus on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

In its recent earnings report, Aligos Therapeutics announced significant progress in its clinical trials and financial results for the second quarter of 2025. The company highlighted the initiation of the Phase 2 B-SUPREME study for its promising HBV treatment, ALG-000184, and shared positive data from its other pipeline candidates.

Key financial metrics revealed that Aligos ended the quarter with $122.9 million in cash, cash equivalents, and investments, providing a solid financial footing for ongoing operations into the second half of 2026. The company reported a net loss of $15.9 million for the quarter, a shift from a net income of $5.1 million in the same period last year. Research and development expenses decreased due to the completion of a MASH Phase 2a trial, while general and administrative expenses also saw a decline.

Strategically, Aligos is advancing its pipeline with ALG-000184 showing potential as a best-in-class therapy for HBV, and ALG-055009 demonstrating significant liver fat reduction in MASH patients. The company is exploring funding options for further development of its coronavirus protease inhibitor, ALG-097558.

Looking forward, Aligos Therapeutics remains committed to its mission of improving patient outcomes through innovative therapies. The management is optimistic about the potential of its pipeline and continues to focus on strategic partnerships and clinical advancements to drive future growth.